VEGFA and neoplasm: Bevacizumab is a monoclonal antibody drug that inhibits vascular growth; its mechanism of action is to block VEGF induced proliferation of vascular endothelial cells and the production of corresponding cytokines, thus inhibiting tumor angiogenesis [8–10].